The stock of Edwards Lifesciences Corp (NYSE: EW) has decreased by -0.23 when compared to last closing price of 70.12. Despite this, the company has experienced a -1.30% fall in its stock price over the last five trading sessions. zacks.com reported 2024-09-02 that Edwards’ first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
Edwards Lifesciences Corp (NYSE: EW) has a price-to-earnings ratio of 28.79x that is above its average ratio. Additionally, the 36-month beta value for EW is 1.13. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 7 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EW is 592.03M and currently, short sellers hold a 1.07% ratio of that float. The average trading volume of EW on September 03, 2024 was 5.06M shares.
EW’s Market Performance
EW stock saw an increase of -1.30% in the past week, with a monthly gain of 13.09% and a quarterly increase of -19.48%. The volatility ratio for the week is 2.82%, and the volatility levels for the last 30 days are 2.86% for Edwards Lifesciences Corp (EW). The simple moving average for the past 20 days is 4.81% for EW’s stock, with a -14.03% simple moving average for the past 200 days.
Analysts’ Opinion of EW
Truist gave a rating of “Hold” to EW, setting the target price at $82 in the report published on July 25th of the current year.
EW Trading at -9.71% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.22% of loss for the given period.
Volatility was left at 2.86%, however, over the last 30 days, the volatility rate increased by 2.82%, as shares surge +15.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.25% lower at present.
During the last 5 trading sessions, EW fell by -1.30%, which changed the moving average for the period of 200-days by +8.30% in comparison to the 20-day moving average, which settled at $67.21. In addition, Edwards Lifesciences Corp saw -8.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from Chopra Daveen, who sale 1,250 shares at the price of $69.95 back on Aug 20 ’24. After this action, Chopra Daveen now owns 29,333 shares of Edwards Lifesciences Corp, valued at $87,438 using the latest closing price.
Chopra Daveen, the Officer of Edwards Lifesciences Corp, proposed sale 1,250 shares at $69.95 during a trade that took place back on Aug 20 ’24, which means that Chopra Daveen is holding shares at $87,438 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.77 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.25. The total capital return value is set at 0.18. Equity return is now at value 21.35, with 15.44 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.4. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 58.31.
Currently, EBITDA for the company is 1.95 billion with net debt to EBITDA at -0.55. When we switch over and look at the enterprise to sales, we see a ratio of 6.87. The receivables turnover for the company is 7.19for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
In conclusion, Edwards Lifesciences Corp (EW) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
